Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Researchers Identify Inflammation's Key Negative Regulator

By BiotechDaily International staff writers
Posted on 23 Apr 2013
Researchers working with a genetically engineered mouse model found that blocking the activity of the enzyme PDE4B (phosphodiesterase 4B) suppressed inflammation by increasing the expression of the deubiquitinase enzyme CYLD (cylindromatosis (turban tumor syndrome)).

The PDE4B gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family. Cyclic nucleotides are important second messengers that regulate and mediate a number of cellular responses to extracellular signals, such as hormones, light, and neurotransmitters. The cyclic nucleotide phosphodiesterases (PDEs) regulate the cellular concentrations of cyclic nucleotides and thereby play a role in signal transduction. This gene encodes a protein that specifically hydrolyzes cAMP. Altered activity of this protein has been associated with schizophrenia and bipolar affective disorder.

The ubiquitin-proteasome system is the mechanism by which malfunctioning and possibly toxic proteins are removed from the cell. This system is based on the tagging of damaged proteins with ubiquitin, and the digestion of the subsequent ubiquinated proteins by the proteasome. CYLD is a protease with endodeubiquitinase activity that specifically cleaves lysine-63-linked polyubiquitin chains, thereby removing the ubiquitin tag. This enzyme is a regulator of pathways leading to NF-kappa-B activation and a mediator of cell survival, proliferation, and differentiation via its effects on NF-kappa-B activation. By being a negative regulator of Wnt signaling CYLD promotes acetylation of alpha-tubulin and stabilization of microtubules and is involved in the regulation of microtubule dynamics. Furthermore, CYLD plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation.

Investigators at Georgia State University (Atlanta, USA) used mice genetically engineered to lack the CYLD gene to determine its role in the process of inflammation.

They reported in the April 9, 2013, online edition of the journal Nature Communications that inhibition of PDE4B markedly enhanced upregulation of CYLD expression in response to bacteria, thereby suggesting that PDE4B acted as a negative regulator for CYLD. In CYLD-deficient mice, inhibition of PDE4B no longer suppressed inflammation. PDE4B negatively regulated CYLD via specific activation of JNK2 (c-Jun N-terminal kinase 2) but not JNK1 (c-Jun N-terminal kinase 1). In addition, postinoculation administration of a PDE4 inhibitor suppressed inflammation in this animal model, thus demonstrating the therapeutic potential of targeting PDE4

The results of this study provide insights into how inflammation is tightly regulated via the inhibition of its negative regulator and may also lead to the development of new anti-inflammatory therapeutics that increase CYLD expression.

"This is the key negative regulator that we have been searching after for years," said senior author Dr. Jian-Dong Li, professor of biology at Georgia State University. "There is a need for better drugs to control inflammation, because current treatments come with serious side effects. Steroids are commonly used, but cannot be used over the long-term, as they suppress the immune system."

Related Links:

Georgia State University



comments powered by Disqus

Channels

Drug Discovery

view channel

Molecule in Green Tea Used as Carrier for Anticancer Proteins

A molecule that is a key ingredient in green tea can be employed as a carrier for anticancer proteins, forming a stable and effective therapeutic nanocomplex. This new discovery could help to construct better drug-delivery systems. Some cancer treatments depend on medication comprising the therapeutic drug and a carrier... Read more

Lab Technologies

view channel
Image: The UC Santa Cruz Ebola Genome Portal contains links to the newly created Ebola browser and to scientific literature on the deadly virus (Photo courtesy of UCSC).

Ebola Genome Browser Now Online to Help Scientists’ Respond to Crisis

A US genomics institute has just released a new Ebola genome browser to help international researchers develop a vaccine and antiserum to help stop the spread of the Ebolavirus. The investigators led... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.